Supplementary Figure 3 from High BCR–ABL/GUS^IS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib

Figure 3. Eight-year estimates of OS (A), TFS (B), FFS (C) and EFS (D) in CML patients expressing high or low BCR-ABL/ABL at diagnosis. The endpoint-specific BCR-ABL/ABL thresholds identified in Supplementary Table 3 were used to divide patients in two groups exhibiting high (dashed line) or low (solid line) BCR-ABL transcripts. Higher BCR-ABL levels were associated with significantly inferior rates of FFS (p<0.005) and EFS (p=0.001) but not OS and TFS. Vertical lines indicate censored patients.